Latest Commercial Expansion News

CONNEQT Health has raised A$5.5 million through a two-tranche placement at a 15.4% discount, backed by key shareholders, to accelerate its commercial expansion and product development.

Wesfarmers outlines a bold growth and productivity agenda centred on AI integration, expanding retail footprints, and lithium project progress, underpinning strong shareholder returns and portfolio resilience.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

EBR Systems has secured A$106.4 million through a fully underwritten institutional placement and entitlement offer, positioning the company for further commercial expansion of its wireless cardiac pacing technology.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Zoono Group has secured its first major commercial orders worth NZ$600,000 from Sharpak under an exclusive UK soft fruits packaging contract, marking a key step in scaling its antimicrobial coating technology in international markets.

Knosys has locked in a two-year, $3.8 million contract extension with ANZ, with full payment received upfront. This deal underpins Knosys’s role in ANZ’s AI integration efforts and strengthens the company’s cash position.

Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

Unith Ltd (ASX:UNT) posted Q3 FY2026 revenue of A$1.26 million, secured a $2 million finance facility to fuel commercial expansion, and showcased significant advancements in its AI Digital Humans platform, including proprietary streaming technology and SDK launches.